Need professional-grade analysis? Visit stockanalysis.com
$22.69B
18.46
5,923
1.57%
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) trades on SHE in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY22.34, down 2.57% from the previous close.
Over the past year, 002262 has traded between a low of CNY20.78 and a high of CNY28.92. The stock has lost 1.1% over this period. It is currently 22.8% below its 52-week high.
Jiangsu Nhwa Pharmaceutical Co Ltd has a market capitalization of $22.69B, with a price-to-earnings ratio of 18.46 and a dividend yield of 1.57%.
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, pregabalin capsules, lacosamide, injection, mivacuride injection, etc. The company's products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China.
Side-by-side comparison against top Healthcare peers.